Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations

Lung Cancer

Volumn 72, Issue 2, 2011, Pages 205-212

  Wu, Jenn Yu ^a   Wu, Shang Gin ^a   Yang, Chih Hsin ^a   Chang, Yih Leong ^a   Chang, Yeun Chung ^a   Hsu, Ya Chieh ^a   Shih, Jin Yuan ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

EGFR; Erlotinib; Gefitinib; Lung cancer; Mutations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 79953781189     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.08.013     Document Type: Article

References (32)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
4. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
5. Yang C.H., Yu C.J., Shih J.Y., Chang Y.C., Hu F.C., Tsai M.C., et al. Specific EGFR mutations predict treatment outcome of stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26:2745-2753.
6. Wu J.Y., Shih J.Y., Yang C.H., Chen K.Y., Ho C.C., Yu C.J., et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010, 126:247-255.
7. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
8. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
9. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
10. Gu D., Scaringe W.A., Li K., Saldivar J.S., Hill K.A., Chen Z., et al. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007, 28:760-770.
11. Wu J.Y., Yu C.J., Yang C.H., Wu S.G., Chiu Y.H., Gow C.H., et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008, 178:847-853.
12. Chan S.K., Gullick W.J., Hill M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006, 42:17-23.
13. Pallis A.G., Voutsina A., Kalikaki A., Souglakos J., Briasoulis E., Murray S., et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 2007, 97:1560-1566.
14. Kim S.T., Lee J., Kim J.H., Won Y.W., Sun J.M., Yun J., et al. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 2010, 116:3025-3033.
15. Perng R.P., Yang C.H., Chen Y.M., Chang G.C., Lin M.C., Hsieh R.K., et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008, 62:78-84.
16. Travis W., Brambilla E., Müller-Hermelink H.K., Harris C.C. Pathology and genetics of tumors of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
18. Wu S.G., Gow C.H., Yu C.J., Chang Y.L., Yang C.H., Hsu Y.C., et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J 2008, 32:924-930.
19. Shih J.Y., Gow C.H., Yu C.J., Yang C.H., Chang Y.L., Tsai M.F., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006, 118:963-969.
20. Gow C.H., Chien C.R., Chang Y.L., Chiu Y.H., Kuo S.H., Shih J.Y., et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clinical Cancer Res 2008, 14:162-168.
21. Wu J.Y., Wu S.G., Yang C.H., Gow C.H., Chang Y.L., Yu C.J., et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Res 2008, 14:4877-4882.
22. Wu J.Y., Yu C.J., Shih J.Y., Yang C.H., Yang P.C. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010, 67:348-354.
23. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
24. Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006, 1:847-855.
25. Ahn J., Kim S., Ahn M., Lee J., Uhm J., Sun J., et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. J Clin Oncol 2010, 28(Suppl.):15s. [abstr 7551].
26. Hirsch F.R., Varella-Garcia M., Bunn P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
27. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
28. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
29. Molina-Vila M.A., Bertran-Alamillo J., Reguart N., Taron M., Castellà E., Llatjós M., et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008, 3:1224-1235.
30. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
31. Hoshi K., Takakura H., Mitani Y., Tatsumi K., Momiyama N., Ichikawa Y., et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 2007, 13:4974-4983.
32. Kimura H., Kasahara K., Kawaishi M., Kunitoh H., Tamura T., Holloway B. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.